Acrivon Therapeutics Inc

ACRV

Company Profile

  • Business description

    Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

  • Contact

    480 Arsenal Way
    Suite 100
    WatertownMA02472
    USA

    T: +1 617 207-8979

    https://www.acrivon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    78

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.4015.50-0.18%
CAC 407,723.4727.200.35%
DAX 4024,073.67286.221.20%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,806.5316.38-0.19%
HKSE23,887.8328.23-0.12%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,587.68223.20-0.56%
NZX 50 Index12,755.749.21-0.07%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,589.3013.70-0.16%
SSE Composite Index3,473.130.810.02%

Market Movers